Clinical data treating multiple solid tumours, including PCa, by targeting IL-8 using HuMax-IL8 (a monoclonal Ab targeting IL-8) showed that inhibition of IL-8 led to a significant reduction in serum IL-8 levels, which was associated with enhanced therapeutic responses [133]. This evidence concerns the gene CXCL8 and posterior cortical atrophy.